CA2159717A1 - Methodes pour modifier la croissance des tissus vivants chez les mammiferes; composes et compositions utiles a cette fin - Google Patents

Methodes pour modifier la croissance des tissus vivants chez les mammiferes; composes et compositions utiles a cette fin

Info

Publication number
CA2159717A1
CA2159717A1 CA002159717A CA2159717A CA2159717A1 CA 2159717 A1 CA2159717 A1 CA 2159717A1 CA 002159717 A CA002159717 A CA 002159717A CA 2159717 A CA2159717 A CA 2159717A CA 2159717 A1 CA2159717 A1 CA 2159717A1
Authority
CA
Canada
Prior art keywords
composition
derivative
deoxyglucose
compositions
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002159717A
Other languages
English (en)
Inventor
Elliot Barnathan
Mary Osbakken
Shunichiro Okada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2159717A1 publication Critical patent/CA2159717A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
CA002159717A 1993-03-31 1994-03-31 Methodes pour modifier la croissance des tissus vivants chez les mammiferes; composes et compositions utiles a cette fin Abandoned CA2159717A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4049893A 1993-03-31 1993-03-31
US08/040,498 1993-03-31

Publications (1)

Publication Number Publication Date
CA2159717A1 true CA2159717A1 (fr) 1994-10-13

Family

ID=21911287

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002159717A Abandoned CA2159717A1 (fr) 1993-03-31 1994-03-31 Methodes pour modifier la croissance des tissus vivants chez les mammiferes; composes et compositions utiles a cette fin

Country Status (6)

Country Link
EP (1) EP0697874A1 (fr)
JP (1) JPH08511041A (fr)
AU (1) AU6553994A (fr)
BR (1) BR9405858A (fr)
CA (1) CA2159717A1 (fr)
WO (1) WO1994022455A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7700819B2 (en) 2001-02-16 2010-04-20 Kci Licensing, Inc. Biocompatible wound dressing
US7763769B2 (en) 2001-02-16 2010-07-27 Kci Licensing, Inc. Biocompatible wound dressing
WO2003086283A2 (fr) * 2002-04-09 2003-10-23 Greenville Hospital System Activite de modulation de metastase d'oligosaccharides hautement sulfates
WO2004058786A1 (fr) * 2002-12-31 2004-07-15 Council Of Scientific And Industrial Research Processus de synthese de deoxy-d-glucose
EP1735326A4 (fr) * 2004-01-29 2011-04-20 Pinnacle Pharmaceuticals Derives de beta-cyclodextrine et leur utilisation contre la toxine letale d'anthrax
ES2590259T3 (es) * 2004-06-17 2016-11-21 Wisconsin Alumni Research Foundation Compuestos y procedimientos para el tratamiento de convulsiones y trastornos paroxísticos
WO2012026614A1 (fr) * 2010-08-24 2012-03-01 国立大学法人宮崎大学 Composition supprimant une activité de métalloprotéinase de matrice
TW201617084A (zh) * 2014-09-25 2016-05-16 山口龍二 包含β－環糊精之抗腫瘤劑
CN113057960B (zh) * 2021-04-15 2022-06-21 浙江理工大学 β-环糊精类衍生化合物在制备促进伤口愈合药物或制剂中的应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH445129A (fr) * 1964-04-29 1967-10-15 Nestle Sa Procédé pour la préparation de composés d'inclusion à poids moléculaire élevé
JPS5036422A (fr) * 1973-08-07 1975-04-05
US4020160A (en) * 1975-08-15 1977-04-26 American Cyanamid Company Cyclodextrin sulfate salts as complement inhibitors
US4066829A (en) * 1976-07-12 1978-01-03 American Cyanamid Company Malto-dextrin poly(H-)sulfates
US4247535A (en) * 1979-11-05 1981-01-27 American Cyanamid Company Modified cyclodextrin sulfate salts as complement inhibitors
US4258180A (en) * 1979-11-05 1981-03-24 American Cyanamid Company C6-Modified cyclodextrin sulfate salts as complement inhibitors
US4383992A (en) * 1982-02-08 1983-05-17 Lipari John M Water-soluble steroid compounds
HU190584B (en) * 1983-03-11 1986-09-29 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara,Rt,Hu Process for the production of heptakis/2,6-di-o-methyl-beta-cyclodextrin
EP0146841A3 (fr) * 1983-12-17 1986-11-20 Consortium für elektrochemische Industrie GmbH Ether mixte de bêta-cyclodextrine soluble dans l'eau et procédé pour sa préparation
DE3346123A1 (de) * 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
US4596795A (en) * 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
JPS61165322A (ja) * 1985-01-14 1986-07-26 Microbial Chem Res Found スパガリン類の注射用凍結乾燥製剤
JPH0651725B2 (ja) * 1985-02-28 1994-07-06 メルシャン株式会社 部分メチル化シクロデキストリン及びその製造方法
GB8506792D0 (en) * 1985-03-15 1985-04-17 Janssen Pharmaceutica Nv Derivatives of y-cyclodextrin
EP0240098A3 (fr) * 1986-04-04 1989-05-10 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Oligo et Polysaccharides pour le traitement des maladies causées par des rétrovirus
GB8613688D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
US4877778A (en) * 1987-07-01 1989-10-31 The Children's Medical Center Corporation Method of enhancing lipophile transport using cyclodextrin derivatives
US4877774A (en) * 1987-09-09 1989-10-31 The United States Of America As Represented By The Department Of Health And Human Services Administration of steroid hormones
DE68910138T2 (de) * 1988-01-19 1994-04-28 Takeda Chemical Industries Ltd Fumagillin als angiostatisches Mittel.
GR1000597B (el) * 1988-01-19 1992-08-26 Judah Moses Folkman Παραγοντας αναστολης αναπτυξης και χρηση του.
US5019562A (en) * 1988-01-19 1991-05-28 The Trustees Of The University Of Pennsylvania/Childrens Hospital Corporation Growth inhibiting agent and the use thereof
US4902788A (en) * 1988-09-29 1990-02-20 Uop Crosslinked cyclodextrins supported on porous refractory inorganic oxides
DK0447171T3 (da) * 1990-03-15 1994-12-12 Tanabe Seiyaku Co Polysulfat af cyclodextrinderivat og fremgangsmåde til fremstilling deraf

Also Published As

Publication number Publication date
WO1994022455A1 (fr) 1994-10-13
JPH08511041A (ja) 1996-11-19
AU6553994A (en) 1994-10-24
EP0697874A1 (fr) 1996-02-28
BR9405858A (pt) 1995-12-12

Similar Documents

Publication Publication Date Title
US5658894A (en) Compositions for inhibiting restenosis
AU678760B2 (en) Methods of inhibiting restenosis
JP4485058B2 (ja) 生体親和性ポリマー、それを含む組成物およびその使用
US5846954A (en) Cyclodextrin compounds and methods of making and use thereof
EP2106263B1 (fr) Dérivés réactifs solubles dans l'eau de carboxy polysaccharides et conjugués à base de carboxy polysaccharides et du fibrinogène
US5510418A (en) Glycosaminoglycan-synthetic polymer conjugates
KR100530196B1 (ko) 구조내 글루쿠론산 유도체 및 글루코사민 유도체를 갖는화합물, 그의 제법 및 그의 용도
Zhou et al. Advances and impact of arginine-based materials in wound healing
Logeart‐Avramoglou et al. Carboxymethyl benzylamide sulfonate dextrans (CMDBS), a family of biospecific polymers endowed with numerous biological properties: a review
US20040185086A1 (en) Polysaccharide-based polymerizable hydrogels
JP2002155137A (ja) 酸化窒素生成ヒドロゲル物質
CA2159717A1 (fr) Methodes pour modifier la croissance des tissus vivants chez les mammiferes; composes et compositions utiles a cette fin
KR100834733B1 (ko) 혈관신생-촉진 단백질 약물에 대한 서방형 국소 약물전달시스템
Jabbari et al. Comprehensive review on biosynthesis of hyaluronic acid with different molecular weights and its biomedical applications
WO1999026984A1 (fr) Modification de l'heparine de faible masse moleculaire et remede contre l'ulcere de la peau
JP2007146178A (ja) キトサン誘導体及び架橋キトサン
US20130084278A1 (en) Water soluble reactive derivatives of carboxy polysaccharides and fibrinogen conjugates thereof
US7041655B1 (en) Capillary membrane stabilization and reduction of tissue injury through use of IV biodegradable macromolecules with antioxidants and/or other chemicals
RU2749509C1 (ru) Таргетное колониестимулирующее средство
JPH06312941A (ja) Ｈｇｆ産生促進剤
EP1527169A2 (fr) Extraits de sangsues pour stents
JPH01501065A (ja) 創傷治癒を刺激するための製剤、該製剤の使用方法及び製造方法
Holmes Percutaneous Access for Peritoneal Dialysis: A Tissue Engineering Approach
Deutsch et al. Development of a biologically active dacron vascular graft surface
Nath et al. A review on regenerating medicine: phytochemical based nanoformulation and its future

Legal Events

Date Code Title Description
FZDE Dead